金陵药业：控股子公司获硫酸钾上市批准

Core Viewpoint - Jinling Pharmaceutical announced that its subsidiary Chizhou Dongsheng Pharmaceutical has received approval from the National Medical Products Administration for the registration of potassium sulfate, which is a raw material for oral solutions used for bowel cleansing before medical procedures. This approval indicates that the raw material meets domestic drug registration requirements and can be produced and sold in the domestic market, enhancing the company's product line in raw materials. However, production and sales will take time, and it will not have a significant impact on the company's current performance [1]. Summary by Relevant Categories - Regulatory Approval: The approval for potassium sulfate registration has been granted by the National Medical Products Administration, allowing for its production and sale in the domestic market [1]. - Product Line Expansion: This approval will enrich the company's raw material product line, providing more options for its offerings [1]. - Impact on Performance: The company indicates that the production and sales of potassium sulfate will take time, and therefore, it will not significantly affect the company's current financial performance [1].